Surprise! Fifth Circuit Rejects DEA’s Longstanding Interpretation of a Pharmacist’s “Corresponding Responsibility” And “Usual Course of Professional Practice” Regulations

Why It Matters

The ruling narrows DEA’s enforcement tools, raising the evidentiary burden for revoking pharmacy registrations and signaling potential nationwide challenges to the agency’s regulatory approach.

Key Takeaways

• Fifth Circuit overturns DEA’s “knowledge” standard for pharmacists
• Liability requires proof prescription was invalid at issuance
• Usual course defined as bona‑fide pharmacy practice, not state care
• DEA must show actual knowledge, not just reason to know
• Decision creates circuit split, may prompt Supreme Court review

Pulse Analysis

The Drug Enforcement Administration has long relied on a broad interpretation of 21 C.F.R. § 1306.04(a) and § 1306.06 to hold pharmacies accountable for dispensing controlled substances that may signal diversion. Under that view, a pharmacist could be penalized simply for “knowing or having reason to know” that a prescription was suspect, and the agency could equate the federal “usual course of professional practice” with a state‑law standard of care. The Fifth Circuit’s recent opinion in Neumann Pharmacy dismantles that approach, insisting that liability hinges on a prescription’s actual invalidity at the moment it is written and on the pharmacist’s subjective awareness of that invalidity.

The court’s three‑prong test—filling, invalidity, and knowledge—re‑anchors the corresponding‑responsibility doctrine in traditional criminal statutes rather than administrative policy. By demanding concrete proof that the prescribing clinician acted outside the “bona‑fide” treatment context, the ruling raises the evidentiary bar for DEA investigators and limits the agency’s reliance on expert testimony about state‑law negligence. This departure creates a clear circuit split, as the Sixth Circuit continues to endorse the broader “knew or should have known” standard. Practitioners and regulators can expect heightened scrutiny of DEA’s enforcement tactics and possible appellate clarification.

For pharmacies operating in the Fifth Circuit, the decision translates into a more defensible compliance posture. Registrants can focus on verifying prescription legitimacy at the point of dispensing and documenting good‑faith reliance on prescriber authority, rather than attempting to anticipate every red flag. Nonetheless, the ruling does not absolve pharmacists from criminal liability when a prescription is demonstrably fraudulent. Industry groups are already urging the DEA to issue revised guidance that aligns with the court’s interpretation, while litigation specialists warn that similar challenges may soon surface in other jurisdictions, potentially prompting a Supreme Court resolution.